All In Biotech

Drug Trial Radar · NCT05190575

TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer

An Open-label, Single-arm Phase II Study to Evaluate the Efficacy and Safety of TST001 for Patients With CLDN18.2 Positive Previously Treated Unresectable Advanced or Metastatic Biliary Tract Cancer

Last checked: Nov 19, 2026Latest source record: Jul 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Jan 14, 2022

Primary completion

May 6, 2023

Study completion May 6, 2023

Sponsor

Lead sponsor
Shanghai Zhongshan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Transcenta Holding Limited
First posted
Jan 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TST001 is a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody. This is an open-label, single-arm phase II study to evaluate the efficacy and safety of TST001 for patients with CLDN18.2 positive previously treated unresectable advanced or metastatic Biliary Tract Cancer.

Conditions

  • Biliary Tract Neoplasms

Interventions

  • TST001Drug

    TST001 IV infusion every 3 weeks until disease progression or other discontinuation criteria.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: 18 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongshan hospital

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.